| Old Articles: <Older 6341-6350 Newer> |
|---|
 |
The Motley Fool
May 21, 2010
Brian Orelli |
Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.   |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
IndustryWeek
May 20, 2010 |
Industrial Methods Can Reduce Health Care Costs Health care providers should heed the lessons learned on the manufacturing floor as they grapple with a costly and complex medical system. |
The Motley Fool
May 20, 2010
Brian Orelli |
FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down. |
The Motley Fool
May 20, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Standpoint Research has just taken the "unprecedented during our seven years in business" move of recommending five stocks at once, all on a single day: Accenture... Dell... Hewlett-Packard... Teva... Xerox... |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
May 19, 2010
Brian Orelli |
A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis. |
Chemistry World
May 18, 2010
Sarah Houlton |
EPA and pharma join forces The US Environmental Protection Agency is working with pharmaceutical companies to improve its ToxCast toxicity prediction tool. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
May 18, 2010
Brian Orelli |
Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now. |
| <Older 6341-6350 Newer> Return to current articles. |
